Schedule of reconciliation of net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
October 29, |
|
October 30, |
|
October 29, |
|
October 30, |
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to shareholders |
|
$ |
(21,298) |
|
$ |
(9,492) |
|
$ |
(45,885) |
|
$ |
(16,970) |
Earnings allocated to participating share awards |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Net loss attributable to common shares — Basic and diluted |
|
$ |
(21,298) |
|
$ |
(9,492) |
|
$ |
(45,885) |
|
$ |
(16,970) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding — Basic (a) (b) |
|
|
29,415,680 |
|
|
21,503,340 |
|
|
25,932,294 |
|
|
18,710,658 |
Dilutive effect of stock options, non-vested shares and warrants |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Weighted average number of common shares outstanding — Diluted |
|
|
29,415,680 |
|
|
21,503,340 |
|
|
25,932,294 |
|
|
18,710,658 |
Net loss per common share |
|
$ |
(0.72) |
|
$ |
(0.44) |
|
$ |
(1.77) |
|
$ |
(0.91) |
Net loss per common share — assuming dilution |
|
$ |
(0.72) |
|
$ |
(0.44) |
|
$ |
(1.77) |
|
$ |
(0.91) |
|
(a) |
For the three and nine-month periods ended October 29, 2022 and October 30, 2021 the basic earnings per share computation included zero and 21,000 outstanding fully paid warrants to purchase shares of the Company’s common stock at a price of $0.001 per share, respectively.
|
|
(b) |
For three and nine-month periods ended October 29, 2022, there were approximately 29,708,057 and 2,181,573 incremental, in-the-money, potentially dilutive common shares outstanding. For three and nine-month periods ended October 30, 2021, there were approximately 658,000 and 992,000 incremental, in-the-money, potentially dilutive common shares outstanding. The incremental in-the-money potentially dilutive common stock shares are excluded from the computation of diluted earnings per share, as the effect of their inclusion would be anti-dilutive.
|
|